eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2026-03-30 23 1 151 159 10.13005/bbra/3487 58721 article Shalini Devaraj 1 Neethirajan Guruswamy 1 Research and Development-Biotechnology, KG College of Arts and Science, Coimabtore,Tamil Nadu, India Eye infection is a major health issue in the world, and it is considered a major cause of preventable visual impairment. Various eye infection therapies are available, but the delivery of these drugs is a challenging task due to anatomical and physiological limitations, leading to poor drug bioavailability and therapeutic response. The traditional eye infection drug delivery system has limitations, such as precorneal loss of the drug, frequent instillation, and poor patient compliance. Recent developments in ophthalmology have introduced various novel eye infection drug delivery systems, such as nanoparticles, niosomes, in situ gelling systems, contact lens-based drug delivery systems, micro-needle technology, and eye infection inserts and implants, including stimuli-sensitive systems. Along with these developments, artificial intelligence (AI) has been integrated into ophthalmology, enabling data science approaches for eye infection therapy, such as formulation optimization, eye infection pharmacokinetics, and selection of anti-microbial agents. Significant potential lies in AI-assisted modelling and machine learning techniques in the development, efficiency, and application of advanced drug delivery systems for the eyes. This review aims to critically discuss the latest developments in advanced drug delivery systems for the eyes in the management of eye infections and the role of AI in improving the accuracy of diagnosis, therapeutic targeting, and therapeutic outcomes. Overall, the application of advanced drug delivery systems and AI has immense potential in improving therapeutic outcomes in eye infections. https://www.biotech-asia.org/vol23no1/ai-enabled-ocular-drug-delivery-systems-for-the-management-of-eye-infections/ Artificial Intelligence; Antimicrobial Therapy; Eye Infections; Nanoparticles-in-situ Gels; Niosomes Ocular Drug Delivery; Sustained Release Systems